Mirxes Holding Co. Ltd., through its wholly-owned subsidiary Mirxes International Holding Limited, has entered into a joint venture agreement with Xeraya Opportunities Fund PCC Limited to establish MYRNA DIAGNOSTICS SDN. BHD. The joint venture will focus on the research, development, commercialization, and regulatory approval of cancer early detection and other nucleic acid-based tests in Malaysia. Mirxes International Holding Limited will hold a 40% stake in the new company, while Xeraya will hold 60%. Both parties have agreed to contribute a total of approximately US$5 million in proportion to their respective equity interests. Additionally, on December 15, 2025, Mirxes Holding Co. Ltd. entered into a strategic partnership with N Health, a member of the Bangkok Dusit Medical Services (BDMS) Group, aiming to introduce advanced microRNA (miRNA) cancer screening solutions to Thailand. This collaboration is expected to enhance early cancer detection and improve patient outcomes across Thailand and the wider region.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirxes Holding Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260205-12016351), on February 05, 2026, and is solely responsible for the information contained therein.